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Objective. Tumor necrosis factor (TNF) increases circulating osteoclast (OC) precursors numbers by promoting their proliferation
and differentiation. The aim of this study was to assess the effect of TNF inhibitors (TNFi) on the differentiation and activity of
OC in rheumatoid arthritis (RA) patients.Methods. Seventeen RA patients treated with TNFi were analyzed at baseline and after a
minimum follow-up period of 6 months. Blood samples were collected to assess receptor activator of nuclear factor kappa-B ligand
(RANKL) surface expression on circulating leukocytes and frequency and phenotype of monocyte subpopulations. Quantification
of serum levels of bone turnover markers, in vitro OC differentiation assays, and qRT-PCR for OC specific genes was performed.
Results. After TNFi therapy, patients had reduced RANKL surface expression in B-lymphocytes and the frequency of circulating
classical CD14brightCD16− monocytes was decreased. Serum levels of sRANKL, sRANKL/OPG ratio, and CTX-I were reduced in
RApatients after TNFi treatment.Moreover, after exposure to TNFi, osteoclast differentiation and activity were decreased, as well as
the expression of TRAF6 and cathepsin K. Conclusion. We propose that TNFi arrests bone loss and erosion, through two pathways:
direct reduction of osteoclast precursor numbers and inhibition of intracellular signaling pathways acting through TRAF6.
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
characterized by systemic inflammation, bone erosion, and
secondary osteoporosis [1].
The immune and skeletal systems have several regulatory
factors in common and immune system cells have a profound
influence on bone metabolism, particularly in the context of
chronic inflammatory diseases. Receptor activator of nuclear
factor-𝜅B ligand is present on osteoblasts’ surface but is also
expressed by activated immune cells, both in its membrane
form and as a soluble molecule [2]. Tumor necrosis factor
(TNF) increases the trafficking of immune system cells
that efflux from bone marrow and peripheral blood into
secondary lymphatic organs and sites of inflammation and
is abundantly found in rheumatoid joints [3]. TNF, together
with other cytokines, acts synergistically with the RANK-
RANKL system [3, 4], further enhancing osteoclast (OC)
differentiation from its circulatory precursors (monocytes)
and contributing to bone resorption [2, 5]. It also increases
the number of circulating OC precursors and the proin-
flammatory cytokine levels in RA patients. These effects are
achieved with low levels of circulating TNF and thus TNF
quantification is frequently unreliable in RA patients [6–8].
Of interest, TNF inhibitors (TNFi) have a beneficial effect
in delaying radiographic damage in RA patients, even in the
absence of clinical improvement, suggesting a specific effect
of TNF inhibition, independent of inflammation control [9].
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Whether this specific effect of TNFi in preventing bone dam-
age in fact occurs independently of the overall inflammatory
burden andwhether it occurs because of reducedOCnumber
and/or function are still unclear.
Our hypothesis was that, in RA patients, TNFi decrease
the OC circulating precursors’ differentiation potential and
activity. Thus, the aim of this study was to assess the effect
of TNFi in the differentiation and activity of OC precursors
in a cohort of RA patients, evaluating also the correlation
between clinical manifestations of inflammation and OC
related parameters.
2. Patients and Methods
2.1. Patients. Patients with RA fulfilling the 2010 Amer-
ican College of Rheumatology/European League Against
Rheumatism criteria [10]were recruited from theRheumatol-
ogy Department, Hospital de Santa Maria, Lisbon Academic
Medical Centre, Portugal. All RA patients included were
TNFi naı¨ve and were followed up during a minimum of 6
months after starting TNFi therapy. Information regarding
patients’ demographics, duration of symptoms, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), tender
and swollen joints counts, presence of erosion, presence of
rheumatoid factor (RF), and presence of anticitrullinated
protein antibodies (ACPA) was collected. Disease activity
score (DAS28-CRP) was evaluated, as well as the Health
Assessment Questionnaire (HAQ) [11].
Heparinized blood and serum samples were analyzed
in baseline and follow-up samples after TNFi treatment
approximately 6 months later. Whole blood samples were
taken for flow cytometry and for isolation of peripheral
blood mononuclear cells (PBMCs). Samples were stored
at the Biobanco-IMM, Lisbon Academic Medical Center,
Lisbon, Portugal. Patients were managed with the standard
practice and all participants gave their informed consent.The
study was approved by the local ethics committee and was
conducted in accordance with the Declaration of Helsinki as
amended in Brazil (2013).
2.2. Flow Cytometry. Identification of B- and T-cells and
granulocytes in peripheral blood, RANKL surface expres-
sion, and immunophenotyping of monocytes in the PBMC
samples were performed using matched combinations of
anti-human murine mAbs as previously described [12].
Heparinized whole blood was used for flow cytometry and
absolute cell counts were calculated from differential leuko-
cyte count determined for all participants. Mononuclear
cells were isolated from freshly drawn peripheral blood
using density gradient centrifugation with Histopaque-
1077 (Sigma-Aldrich). Subpopulations of monocytes were
identified based on the surface expression of CD14 and CD16
[13]. Median fluorescence intensity (MFI) was calculated
based only on positive cells as determined by isotype control
gating. FlowJo software (Tree Star, Stanford University) was
used for analyzing flow cytometry data.
2.3. Bone Turnover Markers and Bone Metabolism Proteins
Detection in the Serum. Carboxyterminal type I collagen
cross links (CTX-I) for bone degradation products, human
type I procollagen amino terminal propeptide (P1NP, Sunred
Biological Technology) for bone formation, sclerostin
(SOST), osteoprotegerin (OPG), Dickkopf-related protein-1
(DKK1), and soluble RANKL (ampli-sRANKL, Biomedica
Gruppe) were analyzed with enzyme-linked immunosorbent
assay [14] in serum samples according to the manufacturer’s
instructions.
2.4. PBMC Isolation and Cell Culture. PBMCs were isolated
by density gradient centrifugation and plated in 96-well
culture plates at a density of 7.0 × 105 cells/well as described
previously [12]. PBMCswere left overnight forOCprecursors
to adhere on bone slices and were further cultured for
21 days with macrophage-colony stimulating factor (M-
CSF, 25 ng/mL, Peprotech), sRANKL (50 ng/mL, Peprotech),
dexamethasone (10 nM, Sigma-Aldrich), and transforming
growth factor-𝛽 (TGF-𝛽, 2.5 ng/mL, R&D Systems), as
described by our group [12]. Adherent cells at day 1 and cells
cultured on bone slices for 7, 14, and 21 days [15] were used for
functional assays and gene expression.
2.5. Functional Assays. OCs were stained for tartrate-
resistant acid phosphatase (TRAP) at days 7, 14, and 21
using the Acid Phosphate Leukocyte Kit (Sigma-Aldrich)
according to the manufacturer’s instructions. Multinuclear
cells containing three or more nuclei [16, 17] were counted as
TRAP positive OCs. After visualization, cells were removed
from bone slices using sodium hypochlorite and stained
with 0.1% toluidine blue for the measurement of resorbed
area at days 7, 14, and 21 of culture [18]. Bone slices were
photographed in an area of 1.25mm2 with a bright field
microscope (Leica DM2500, Leica). The number of TRAP
stained OCs was counted at each time point and resorption
pits were traced using ImageJ software (NIH, Bethesda,MD).
The resorbed area was expressed in % of total area.
2.6. Gene Expression. RNA was extracted from cells cul-
tured over bone slices at days 1, 7, 14, and 21 of cul-
ture using NZYol (NZYTech) and complementary (c)DNA
was synthesized as described previously [12]. Genes that
encode osteoclast proteins such as RANK, TNF-receptor
associated factor-6 (TRAF6), Fos-related antigen-2 (FRA-
2), a subunit of H+-dependent ATPase (ATP6V0D2), TRAP,
and cathepsin K (CTSK) were studied by real-time quan-
titative PCR (RT-qPCR) using the DyNAmo Flash SYBR
Green qPCR Kit (Thermo Scientific). Primers (Suppl. Table 1
in Supplementary Material available online at https://doi
.org/10.1155/2017/2690402) were designed using the primer-
BLAST software [19]. The results were normalized with the
housekeeping gene ribosomal RNA 18s and the standard
curve method was used to determine the efficiency of qPCR
as described previously [20, 21].
2.7. Statistical Analysis. Statistical analysis was performed
with SPSS Statistics 17.0 (IBM) and GraphPad Prism
5 (GraphPad Software Inc.). Categorical variables were
expressed as frequencies and comparisons were tested using
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Table 1: Baseline and follow-up characteristics of patients.
RA patients (𝑛 = 17)
𝑝-value
Baseline Follow-up
Age (years) 50 [38–63] —
% Females 71% —
Symptoms duration (years) 6 [3.5–9.5] —
Rheumatoid factor (% positive) 71 —
ACPA (% positive) 53 —
Erosive (% y) 59 —
Treatment with NSAIDs (% y) 47 —
Treatment with DMARD (% y) 100 —
DMARD duration (months) 15 [3–51] —
ESR (mm/h) 28 [18–48] 21 [13–26] 0.0257
CRP (mg/dl) 1.4 [0.7–2.0] 0.3 [0.04–0.8] 0.0018
Tender joint count 9 [4–14] 0 [0–2] 0.0005
Swollen joint count 7 [4–9] 0 [0-0] 0.0005
DAS28-CRP 5.6 [5.2–6.3] 2.9 [2.2–3.5] <0.0001
HAQ 1.7 [0.8–2.0] 0.1 [0.0–1.0] 0.0059
TNFi duration (months) — 6 [6–12] —
Data is represented as median [Interquartile range] unless stated otherwise; 𝑝-value < 0.05 is considered significant; ACPA - anti-citrullinated protein antibod-
ies; CRP – C-reactive protein; DAS – disease activity score; DMARDs – disease modifying antirheumatic drugs; ESR – erythrocyte sedimentation rate; HAQ -
Health assessment questionnaire; NSAIDs - non-steroidal anti-inflammatory drugs; RA – rheumatoid arthritis; TNFi – tumor necrosis factor inhibitors; y – yes.
Table 2: Monocyte subpopulation frequency and osteoclastogenic marker expression.
Baseline Follow-up 𝑝 value
Classic (%)a 88 [82–89] 78 [70–83] 0.0065∗∗
Classic CD51/CD61 MFI 130 [119–148] 125 [111–137] 0.4258
Classic RANKMFI 133 [116–160] 122 [100–135] 0.1849
Intermediate (%)a 4.4 [2.4–5.6] 4.0 [2.1–7.1] 0.6013
Intermediate CD51/CD61 MFI 222 [139–400] 193 [146–240] 0.8203
Intermediate RANKMFI 197 [117–361] 188 [120–272] 0.9102
Nonclassic (%)a 5.7 [4.1–11] 14 [11.5–18.1] 0.0005∗∗∗,†
Nonclassic CD51/CD61 MFI 192 [80–290] 142 [127–167] 0.5703
Nonclassic RANKMFI 139 [122–157] 138 [126–146] 1.0000
Flow cytometry results are shown as median and interquartile range; agated on the monocyte subpopulation from peripheral bloodmononuclear cells. RANK:
receptor activator of nuclear factor-𝜅B; MFI: median fluorescence intensity (arbitrary units); ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001. †Remained significant after correction
for multiple comparisons.
chi-square test. Continuous variables were expressed by
median and interquartile range. Spearman’s correlations were
performed between the analyzed parameters and clinical
variables (ESR, CRP, tender and swollen joint count, and
DAS28). Baseline and follow-up values of each sample were
compared using Wilcoxon’s matched-pairs signed-rank test
or paired 𝑡-test according to normal distribution. 𝑝 value less
than 0.05 was considered significant.
3. Results
3.1. Patient Background. Seventeen RA patients, evaluated
before and after starting TNFi therapy, were included in this
study. All patients were receiving methotrexate (10–20mg
weekly), 15 of whom were also under low dose prednisolone
and 2 were additionally under bisphosphonates. These ther-
apies had been introduced more than 6 months before TNFi
was started and were stable over the study period. Patients
were treated with one of four TNFi: one of the monoclonal
antibodies (adalimumab, golimumab, or infliximab; 41%)
or etanercept (59%). A blood sample was obtained before
the start of TNFi and after at least 6 months of treatment.
Thirteen patients (76%) were good responders to TNFi and
4 (24%) were moderate responders according to the EULAR
response criteria [22]. Joint counts, ESR, CRP, DAS28, and
HAQ were significantly decreased after TNFi therapy. The
clinical and demographic characteristics of patients both at
baseline and at follow-up are described in Table 1.
3.2. TNFi Treatment in RA Patients Decreases the Frequency
of Circulating Osteoclast Precursors. After TNFi treatment,
the frequency of the classical monocyte subpopulation
(CD14brightCD16−) was decreased (𝑝 = 0.0065; Table 2) and
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Table 3: Whole blood cell distribution and RANKL expression.
Baseline Follow-up 𝑝 value
Neutrophils (%)a 82 [71–91] 90 [84–091] 0.2662
Neutrophils (×108 cells/L) 12.7 [8.0–15.6] 9.6 [8.4–12.9] 0.2642
RANKL+ neutrophils (%)b 22 [3–41] 53 [21–77] 0.0856
RANKL+ neutrophils (×108 cells/L) 1.5 [0.3–4.3] 5.9 [1.8–7.1] 0.1475
Neutrophil RANKL MFI 33.2 [25.5–44.9] 24.1 [21.7–28] 0.0830
T-cells (%)c 62 [58–74] 68 [52–72] 0.5265
T-cells (×108 cells/L) 4.2 [2.4–5.2] 3.4 [2.4–11.7] 0.4131
RANKL+ T-cells (%)b 6.2 [0.8–24] 6.7 [4.6–15.7] 0.8984
RANKL+ T-cells (×108 cells/L) 0.30 [0.03–1.03] 0.20 [0.16–0.69] 0.7646
T-cell RANKL MFI 49 [41–55] 32 [25–53] 0.2061
B-cells (%)c 7.3 [4.8–14] 9.2 [4.9–15.0] 0.7364
B-cells (×108 cells/L) 0.40 [0.18–0.94] 0.44 [0.23–1.51] 0.9658
RANKL+ B-cells (%) 4.7 [2.0–6.7] 14 [3–28] 0.0088∗∗
RANKL+ B-cells (×108 cells/L)b 0.02 [0.01–0.06] 0.06 [0.02–1.22] 0.0029∗∗,†
B-cell RANKL MFI 48 [38–80] 30 [25–63] 0.0401∗
Flow cytometry results are shown as median and interquartile range; agated on granulocytes from whole blood; bgated on the correspondent parent gate
(neutrophil, T- or B-cell); cgated on the nongranulocyte cells from whole blood (also called the “monolymph” gate). RANKL: receptor activator of NF-𝜅𝛽
ligand; MFI: median fluorescence intensity (arbitrary units); ∗𝑝 < 0.05, ∗∗𝑝 < 0.01. †Remained significant after correction for multiple comparisons.
Table 4: Serum levels of bone turnover markers and bone metabolism proteins.
Baseline Follow-up 𝑝 value
sRANKL (pmol/L) 0.32 [0.21–0.67] 0.18 [0.11–0.35] 0.0085∗∗
OPG (pmol/L) 4.34 [2.60–5.82] 4.22 [3.05–5.08] 0.7990
sRANKL/OPG 0.08 [0.04–0.17] 0.05 [0.03–0.07] 0.0031∗∗,†
DKK1 (pmol/L) 25.5 [18.1–43.3] 26.4 [21.9–31.7] 1.000
Sclerostin (pmol/L) 25.2 [16.94–33.8] 25.2 [19.2–29.3] 0.8577
CTX-I (ng/mL) 194.6 [176.6–430.7] 163.6 [152.1–173.9] 0.0005∗∗∗,†
P1NP (ng/mL) 55.7 [46.3–61.3] 45.8 [39.6–48.9] 0.0252∗
CTX/P1NP 3.36 [3.09–3.82] 3.71 [3.34–4.30] 0.5590
Enzyme-linked immunosorbent assay results are shown as median and interquartile range. sRANKL: soluble receptor activator of NF-𝜅𝛽 ligand; OPG:
osteoprotegerin; DKK1: Dickkopf-related protein-1: CTX: carboxyterminal telopeptide of type I collagen; P1NP: total procollagen type 1N-terminal propeptide;
∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001. †Remained significant after correction for multiple comparisons.
that of the nonclassical subpopulation (CD14dimCD16+) was
increased (𝑝 = 0.0005) [13]. No differences were identified in
either CD51/CD61 (𝛼v𝛽3 integrin) or RANK surface expres-
sion. After statistical correction for multiple comparisons,
only the increase in the nonclassical subpopulation remained
significant.
RANKL surface staining was performed in CD66b+ neu-
trophils, CD3+ T-cells, andCD19+ B-cells (Table 3). No differ-
ence was found in the total number of circulating neutrophils
and T- or B-cells after therapy. Although the frequency of
RANKL+ neutrophils or T-cells was not significantly different
after treatment, both frequency and absolute number of
RANKL+ B-cells were higher after treatment (𝑝 = 0.0088 and
0.0029, resp.). However, B-cell RANKL surface expression
was significantly decreased after treatment (𝑝 = 0.0401).
When statistically corrected for multiple comparisons, the
increase in RANKL+ B-cells remained significant.
3.3.The sRANKL/OPGRatio andCTX-I Circulating Levels Are
Reduced in RA Patients after TNFi Treatment. Circulating
levels of sRANKL were significantly decreased after TNFi
(𝑝 = 0.0085; Table 4), leading to decreased sRANKL/OPG
ratio (𝑝 = 0.0031). We found no differences in the circulating
levels of DKK1 or SOST. CTX-I and P1NP levels were lower in
patients at 6months of follow-up, when compared to patients
at baseline (𝑝 = 0.0005 and 0.0252, resp.), and no difference
was found in the CTX-I/P1NP ratio. After correcting for
multiple comparisons, the differences in sRANKL/OPG and
CTX-I after treatment remained significant.
3.4. Osteoclast Differentiation and Activity in RA Patients
Are Decreased after TNFi Treatment due to Decreased TNF
Intracellular Signaling and Cathepsin K Expression. Under
stimulating conditions, adhering precursors from patients
treated with TNFi formed fewer OCs than adhering precur-
sors from patients at baseline (𝑝 = 0.0094 at culture day 14,
𝑝 = 0.0203 at culture day 21; Figure 1).
Although the number of resorption pits was not signifi-
cantly different before and after treatment, the area resorbed
per pit was significantly reduced in cultures from patients
BioMed Research International 5
Resorption pit
Resorption assayTRAP staining
Baseline
Follow-up
Osteoclast
(a)
OC d7 OC d14 OC d21
0
10
20
30
OC d7 OC d14 OC d21
0
10
20
30
40
50
60
70
OC d7 OC d14 OC d21
0
1000
2000
3000
Baseline
Follow-up
Baseline
Follow-up
Baseline
Follow-up
Baseline
Follow-up
OC d7 OC d14 OC d21
0
10
20
%
 o
f r
es
or
be
d 
ar
ea
∗∗∗p = 0.0038
O
C 
nu
m
be
r/
m
m
2
Pi
t n
um
be
r/
m
m
2
∗∗ ∗
∗
∗p = 0.0203
∗p = 0.0383
Re
so
rb
ed
 ar
ea
/p
it 
(𝜇
m
2
)
∗∗∗, 𝜏
∗∗p = 0.0094
(b)
Figure 1: Functional assays of in vitro differentiated OC. (a) Representative images, at culture day 21, of adhering precursors stimulated with
M-CSF, RANKL, dexamethasone, and TGF-𝛽 stained for TRAP, where the pit assay was performed. (b) OC number increased throughout
time and, at culture days 14 and 21, patients at follow-up had significantly fewer osteoclasts than at baseline (𝑝 = 0.0094 and 0.0203, resp.). No
differences were found in the number of resorption pits/mm2; patients at follow-up had significantly smaller pits at culture day 21 (resorbed
area/pit, 𝑝 = 0.0038) and significantly less resorbed area at culture day 21, when compared to their baseline (𝑝 = 0.0383). Dots represent
median counts for each group at each time point and bars represent interquartile range. d: day; OC: osteoclast. Scale bars: 100𝜇m; red arrows:
osteoclasts; black arrows: resorption pits. 𝜏: remained significant after adjusting for multiple comparisons.
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Figure 2: Gene expression profile of stimulated adhering precursors in culture for 21 days. At day 1, TRAF6 expression in patients at follow-
up was significantly reduced (𝑝 = 0.0229). At day 7, both FRA-2 and CTSK expressions were significantly decreased (𝑝 = 0.0242 and
0.035, resp.). At day 21, patients at follow-up had significantly reduced expression when compared to patients at baseline (𝑝 = 0.008). Gene
expression shown as a ratio to housekeeping expression (2(−ΔCT)/2(−ΔCT)). Dots in graphs representmedian gene expression for each group
at each time point and lines represent interquartile range [25–75]. d: day; TRAF6: gene encoding tumor necrosis factor receptor-associated
factor-6; FRA-2: gene encoding Fos-related antigen-2; CTSK: gene encoding cathepsin K. 𝜏: remained significant after adjusting for multiple
comparisons.
at follow-up at culture day 21 (𝑝 = 0.0038), which resulted
in significantly decreased total resorbed area (𝑝 = 0.0383).
After statistical correction for multiple comparisons, only the
differences in OC number at day 14 and the resorbed area per
pit at day 21 remained significant.
Gene expression by RT-qPCR was performed for OC
genes that are known to be important during the adhering
precursors’ differentiation and OC activity. At culture day 1,
TRAF6 expression in patients at follow-up was significantly
lower than in patients at baseline (𝑝 = 0.0229; Figure 2).
At culture day 7, expression of both FRA-2 and CTSK was
significantly decreased after TNFi treatment (𝑝 = 0.0242 and
0.0350, resp.). No differences were found in any of the studied
genes at culture day 14, but at culture day 21 there was a
significant decrease in CTSK expression in the differentiated
OC from patients after treatment. This difference in CTSK
expression remained significant after multiple comparisons
adjustment.
No differences were found in any of the studied param-
eters when comparing monoclonal antibodies (adalimumab,
infliximab, or golimumab) with the fusion protein etanercept
(data not shown). No correlation was found between clinical
or laboratorial inflammatory parameters for any of the
studied variables.
4. Discussion
With this study, we aimed to test the effect of TNFi in the
differentiation and activity of OC precursors in RA patients.
We have shown that RA patients treated with TNFi have
reduced frequency of classic monocytes. We also found a
decrease in the circulating levels of soluble RANKL and con-
sequently a reduction in the sRANKL/OPG ratio after TNFi
treatment. Although no differences in circulating levels of
SOST or DKK1 were detected, serum CTX-I and P1NP levels
were decreased after TNFi treatment, reflecting decreased
bone turnover in these patients. Accordingly, we found that
the ex vivo differentiation and resorptive activity of OC
precursors from TNFi-treated patients were reduced, mainly
due to early downregulation of TNF signaling proteins, such
as TRAF6 or FRA-2, and to a later reduction of CTSK
expression. Moreover, when comparing all studied parame-
ters, we found no differences between the use of monoclonal
antibodies (adalimumab, golimumab, and infliximab) and
the fusion protein [23], suggesting that they have similar
effects onOCprecursors. Previous studies have compared the
effects of different TNFi in disease activity, sRANKL/OPG
ratio, and circulating leukocytes without finding significant
differences [24, 25]. It has been previously reported that
granulocyte numbers were reduced in circulation after 2 and
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14 weeks of infliximab treatment [26]; however, this study
identified granulocytes as CD16+ cells instead of CD66b+
cells. We found no significant differences in the frequency of
neutrophils and T-lymphocytes or in RANKL surface expres-
sion in these cells, but we observed a significant increase
in RANKL+ B-lymphocytes accompanied by a decrease in
RANKL surface expression. There have been a number of
studies addressing the effect of TNFi in RA patients’ periph-
eral lymphocytes; however, there is no consensus among
different reports, mainly due to sampling differences. In 2005,
Toubi and colleagues have shown that infliximab decreased
apoptosis in Tregs of RA patients [27]. Other studies showed
that short in vitro exposure of PBMCs to infliximab or
etanercept had no effect in peripheral lymphocyte apoptosis
[28] or in synovial membrane biopsies [29]. It has previously
been shown that RA patients under TNFi have increased
number of T-regulatory cells and a reduced number of T-
effector cells [30]. Other studies showed that in TNFi-treated
RA patients there were no changes in T-regulatory cells
frequency [24] or in the frequency of total T-cells,monocytes,
or granulocytes and only a transient unspecified effect on B-
cells [31]. To our knowledge, a comparative study of RANKL
expression in RA patients before and after therapy with TNFi
has never been published.
Three monocytes subpopulations, based on their expres-
sion of CD14 and CD16 surface markers, have been described
in humans [13]. In RA patients, it has been shown that
the intermediate subpopulation is increased when com-
pared to healthy donors [13] and apoptosis of local and
peripheral monocytes/macrophages was also increased after
etanercept or infliximab treatment [29, 32]. Another study
has shown no differences in CD14dim or CD14bright sub-
populations after 4 months of infliximab therapy [26]. In
our cohort, 6 months after TNFi therapy, patients showed
decreased classic (CD14brightCD16−) and increased nonclas-
sical (CD14dimCD16+) subpopulations. These changes in
frequency were accompanied by a nonsignificant decrease in
CD51/CD61 (𝛼v𝛽3 integrin) and RANK surface expression
in all subsets. In accordance with our results, a recent study
showed a reduction in classical monocyte subpopulation
and an increase in the nonclassical subpopulation following
infliximab therapy [33]. Moreover, Sprangers et al. observed
that although nonclassical monocytes can also differentiate
into OC, these cells have lower resorptive ability [34], which
might explain why we did not observe bone resorption
increase.
Patients under TNFi had reduced levels of sRANKL,
sRANKL/OPG, CTX-I, and P1NP, suggesting a decrease in
OC activity and a return to balanced coupling of bone
resorption and bone formation. No differences were found
in the circulating levels of DKK1 and SOST after TNFi
treatment. Previous studies have shown discrepancies in the
determination of these bone remodeling-associated proteins.
Studies have found no differences in sRANKL or OPG
serum levels after infliximab or etanercept [35, 36]. However,
contradictory results have emerged regarding both OPG and
sRANKL circulating levels after TNFi therapy [37, 38]. DKK1
and sclerostin have a direct effect on bone formation through
interaction with the Wnt signaling pathway [39] but they
have not been extensively studied in RA patients under
TNFi. Previous reports have shown that etanercept has no
effect on circulating levels of DKK1 but it increases sclerostin
in circulation after treatment [35]. However, infliximab has
been shown to decrease DKK1 levels in patients responding
to therapy [40]. It has been previously shown that TNFi
have a beneficial effect, reducing radiographic damage in RA
patients, even in the absence of clinical improvement [9, 41].
Reports have described a decrease in CTX-I or urinarymark-
ers of bone resorption after TNFi therapy [35, 42]. However,
some discrepancies have been found when studying bone
formation markers. Studies with etanercept and infliximab
showed no alteration in circulating P1NP levels after treat-
ment [35, 42], while another study with etanercept showed
reduced levels of urinary bone formation markers [43].
Although the classical monocyte subpopulation has been
considered the OC precursor subset, all three subpopulations
can differentiate in vitro into OC [44]. To understand the
effect of TNFi in OC differentiation and function, we isolated
PBMCs from RA patients before and after TNFi treatment
and cultured them in vitro over bone slices. After TNFi
treatment, we found a decrease in OC number and both
in the total resorbed area and in the average resorbed area
per pit. No differences in pit number and in the number
of nuclei/OCs, aspects associated with OC activity, were
identified [45].These observations suggest that TNFi reduces
the number and mobility of OCs.
Complex in vivo studies with animal models also showed
that infliximab and etanercept reduced the bone resorbed
area [46, 47] and etanercept decreased 𝛼v𝛽3 integrin expres-
sion [48]. In a study similar to ours, Gengenbacher and
colleagues studied RA patients under infliximab therapy for
6 months and observed decreased pit number after in vitro
cell culture in OC differentiating conditions [36]. There have
been reports that infliximab inhibits directly (in vitro)murine
and human OC formation [49, 50]. Other authors show that
although TNFi reduce the number of murine pre-OCs in
vitro, there is no effect in the total number of formedOCs [51].
Another study has shown that infliximab directly inhibits OC
formation in high density healthy PBMC cultures without
any further stimuli [52]. Etanercept was also shown to inhibit
in vitro OC formation induced by M-CSF and IL-23 from
healthy subjects [53]. Controversially, Takita and colleagues
cultured PBMCs fromRA patients, exposing them toM-CSF,
RANKL, and infliximab in vitro, and observed that infliximab
increased bone resorption when compared to M-CSF and
RANKL alone [54].
There is evidence that TNF contributes to expression
of specific OC proteins and that it directly activates OC
differentiation through cross activation of theNF-𝜅Bpathway
or c-Jun N-terminal kinase (JNK) signaling cascade [55]. We
were interested in understanding the underlyingmechanisms
of reduced OC formation and bone resorption after TNFi,
so we conducted gene expression assays and observed that
OC precursors from RA patients after TNFi exposure had
decreased expression of TRAF6 at culture day 1, followed
by a reduction of FRA-2 and CTSK at day 7, and finally
decreased expression of CTSK at culture day 21, when
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compared to patients before TNFi exposure. RANK/RANKL
signaling cross-talks with TNF signaling, as RANK is a TNF-
superfamily member [56]. Upon activation, both RANK
and TNF activate cytoplasmic kinases and adaptor proteins,
including TRAF6, which further activate FRA-2 [57]. FRA-2
is a protein that when associated with Fos and AP-1 promotes
the transcription of OC differentiating genes, including
CTSK [58]. In TNFi-treated patients, we have observed not
only a decrease in serum CTX-I (cleaved by CTSK), but also
a reduction in CTSK expression after adhering precursors
differentiation in vitro, as well as a decline in the resorbed
area/OC. This has previously been observed in a RA patient
with concomitant pycnodysostosis, an autosomal recessive
mutation in the cathepsin K gene characterized by absence
of this enzyme. Osteoclasts from these patients form very
small resorbing pits and do not release CTX-I into the culture
media [59].
Themain limitations of this work were the lack of healthy
controls and the reduced number of patients and the diversity
of TNF blockers studied, which we tried to overcome by
studying the same patient before and after therapy.
Taken together with the results found in the literature,
these findings suggest that TNFi decrease bone resorption,
independently of the control of disease activity. We propose
that this is due to the direct reduction of OC classical precur-
sors and downregulation of intracellular signaling pathways
involving TRAF6 resulting in a reduction of CTSK expression
and consequent lack of OC motility. Further investigation of
the signaling pathways involving TRAF6, such as the ASK1-
TRAF6 interaction, is of clear interest in this context.
Additional Points
Key Messages. (i) TNFi decrease bone resorption through
the direct reduction of OC precursor numbers. (ii) TNFi
downregulate the intracellular signaling pathways involving
TRAF6 resulting in a reduction of CTSK expression and
consequent lack of OC motility.
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